3 recruiting, 2 completed, 1 active not recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Relapsed Osteosarcoma: new trials by email Literature Review of Relapsed Osteosarcoma trials Research Report on Relapsed Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-07-15 | 2026-07-21 |
| Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma Tegavivint, Gemcitabine - Osteosarcoma Recurrent, Osteosarcoma in Children | Phase 1 | Recruiting | Emory University | 24 | 2026-01-22 | 2026-10-19 |
| Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate - Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Emory University | 24 | 2023-11-06 | 2025-12-26 |
| Cabozantinib With Topotecan-Cyclophosphamide Cabozantinib, Topotecan, Cyclophosphamide - Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 12 | 2020-12-23 | 2023-02-15 |
| C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) C7R-GD2.CART cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 94 | 2019-04-23 | 2026-07-06 |
| Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma Sorafenib, Everolimus - Metastatic Osteosarcoma, Relapsed Osteosarcoma | Phase 2 | Completed | Italian Sarcoma Group | 38 | 2011-06-01 | 2015-06-17 |
Osteosarcoma (6) · Neuroblastoma (3) · Sarcoma (2) · Sarcoma, Ewing (2) · Breast Neoplasms (1) · Phyllodes Tumor (1) · Rhabdomyosarcoma (1) · Uveal Melanoma (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Bone Tissue (6) · Neoplasms, Connective Tissue (6) · Neoplasms, Connective and Soft Tissue (6) · Sarcoma (4) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neoplasms, Neuroepithelial (3) · Neuroectodermal Tumors (3) · Neuroectodermal Tumors, Primitive (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Breast Diseases (1) · Eye Diseases (1)
Cyclophosphamide (1) · Everolimus (1) · Filgrastim (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Irinotecan (1) · Sorafenib (1) · Temozolomide (1) · Topotecan (1) · Zoledronic Acid (1) · cabozantinib (1) · dinutuximab (1) · pegfilgrastim (1)
Baylor College of Medicine (2) · Emory University (2) · Dana-Farber Cancer Institute (1) · Italian Sarcoma Group (1)
United States (5) · Italy (1)
Bilal Omer, MD (1) · Giovanni Grignani, MD (1) · Kelly Goldsmith, MD (1) · Leander D Timothy, MD (1) · Massimo Aglietta, MD (1) · Piero Picci, MD (1) · Shoba A Navai, MD (1) · Stephanie L Fetzko, MD (1) · Steven C DuBois, MD (1) · Thomas Cash, MD, MSc (1)